Catalyst Calendar

Mon, Sep 14, 2026

1 updates

4:00 AM

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year 1 Gotistobart demonstrated a median

Presentation / Abstract • Phase 3WCLC presentation Mon, Sep 14, 2026biontech.de

Thu, Aug 27, 2026

2 updates

BNTX

4:30 PM

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to this season’s vaccine NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc.

biontech.de

BNTX

4:30 PM

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

biontech.de

Thu, Aug 20, 2026

1 updates

BNTX

5:30 AM

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in novel-novel combination treatment strategies Updated overall survival data for

Presentation / Abstract • Phase 1/2WCLC oral presentation Tue, Sep 15, 2026, 12:30 PM KSTbiontech.de

Tue, Aug 4, 2026

1 updates

BNTX

6:45 AM

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types Multiple milestones

biontech.de

Mon, Aug 3, 2026

1 updates

BNTX

5:00 AM

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (“CEO”), who will take office by February 1, 2027, at the

biontech.de

Wed, Jul 29, 2026

1 updates

BNTX

4:30 PM

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable

biontech.de

Tue, Jul 21, 2026

1 updates

BNTX

6:45 AM

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

MAINZ, Germany, July 21, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m.

biontech.de